Showing 2001-2010 of 5696 results for "".
- Iveric bio Announces Fast Track Designation From FDA for Zimura for Treatment of Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bio-announces-fast-track-designation-from-fda-for-zimura-for-treatment-of-geographic-atrophy-secondary-to-dry-amd/2477528/Iveric bio announced that the FDA has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Currently, there is no FDA or EMA appro
- SightGlass Vision Reports Positive Interim Data From Pivotal Clinical Trial of Novel Eyeglasses for Myopia Management in Childrenhttps://modernod.com/news/sightglass-vision-reports-positive-interim-data-from-pivotal-clinical-trial-of-novel-eyeglasses-for-myopia-management-in-children/2477515/SightGlass Vision announced topline results from a planned 12-month interim analysis of the company’s pivotal trial evaluating its novel eyeglasses designed to slow the progression of myopia in children. Data from the Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety
- Tatsuya Kaihara Appointed CEO of Santen Inc. and Head of North America Business of Santen Pharmaceuticalhttps://modernod.com/news/tatsuya-kaihara-appointed-ceo-of-santen-inc-and-head-of-north-america-business-of-santen-pharmaceutical/2477510/Santen announced the appointment of Tatsuya Kaihara as Corporate Officer and Head of North America Business of Santen Pharmaceutical. As of April 1, he is also appointed as CEO of Santen Inc. and he will lead the company’s North America business and report to Shigeo Taniuchi, P
- US Department of Labor Provides Guidance on Paid Sick and Family Leavehttps://modernod.com/news/us-department-of-labor-provides-guidance-on-paid-sick-and-family-leave/2477487/The Department of Labor just updated its ‘Questions and Answers’ on paid sick and family leave during the COVID-19 pandemic. This includes guidance on: (i) teleworking, furloughs, layoffs, reduced schedules, and office closures (employees are not eligible for paid sick o
- Novartis, Mylan and Teva to Supply Tens of Millions of Chloroquine Tablets to Fight COVID-19https://modernod.com/news/novartis-mylan-and-teva-to-supply-tens-of-millions-of-chloroquine-tablets-to-fight-covid-19/2477430/As efforts to discover new COVID-19 medicines roll on, President Donald Trump and others this week focused attention on the decades-old malaria drug chloroquine. Bayer got things rolling with an initial donation of the drug, and now Novartis, Mylan and Teva are takin
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- WHO Declares COVID-19 Outbreak a Pandemic; Eye Care Meetings Cancelledhttps://modernod.com/news/who-declares-covid-19-outbreak-a-pandemic/2477374/The World Health Organization on Wednesday said the COVID-19 outbreak can now “be characterized as a pandemic.” The declaration by Director-General Tedros Adhanom Ghebreyesus was made after he noted that “in the past 2 weeks the number of cases outside China has increased thirteen-fold and the nu
- Novartis Responds to ASRS Note Raising Safety Concerns With Wet AMD Drug Beovuhttps://modernod.com/news/novartis-responds-to-asrs-note-raising-safety-concerns-of-beovu/2477325/Novartis confirmed to Eyewire News that it is launching an internal and external review of new information that raises serious safety concerns over its wet age-related macular degeneration (AMD) drug Beovu (brolucizumab). On February 23, the American Society of Retinal Specialists (ASRS) s
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to